HKSE - Delayed Quote HKD

LIVZON PHARMA (1513.HK)

26.700
+0.300
+(1.14%)
At close: 4:08:33 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
11,750,071.940
11,812,338.855
12,430,038.326
12,629,579.048
12,063,863.273
Cost of Revenue
4,049,948.231
4,081,106.957
4,465,473.361
4,461,283.076
4,253,087.484
Gross Profit
7,700,123.710
7,731,231.898
7,964,564.965
8,168,295.972
7,810,775.789
Operating Expense
4,752,707.065
4,901,107.721
5,533,852.905
5,933,892.236
5,623,144.495
Operating Income
2,947,416.645
2,830,124.177
2,430,712.059
2,234,403.736
2,187,631.294
Net Non Operating Interest Income Expense
156,477.643
154,945.598
261,270.256
212,078.919
74,323.083
Pretax Income
2,920,294.753
2,806,146.268
2,382,666.546
2,330,550.610
2,245,688.830
Tax Provision
528,246.776
501,661.315
485,065.534
374,973.228
293,587.661
Net Income Common Stockholders
2,089,979.926
2,061,095.804
1,953,650.833
1,909,407.688
1,775,683.251
Basic EPS
2.30
2.24
2.10
2.04
1.90
Diluted EPS
2.30
2.24
2.10
2.04
1.90
Basic Average Shares
910,546.601
920,132.055
930,309.921
935,984.161
934,570.132
Diluted Average Shares
910,546.601
920,132.055
930,309.921
935,984.161
934,570.132
Total Operating Income as Reported
2,954,438.166
2,844,400.261
2,415,108.490
2,350,555.618
2,266,989.995
Total Expenses
8,802,655.295
8,982,214.678
9,999,326.267
10,395,175.312
9,876,231.979
Net Income from Continuing & Discontinued Operation
2,089,979.926
2,061,095.804
1,953,650.833
1,909,407.688
1,775,683.251
Normalized Income
2,223,756.970
2,191,671.750
2,232,037.258
2,074,001.728
1,845,367.069
Interest Income
243,194.166
247,956.637
368,159.120
315,137.488
162,189.969
Interest Expense
80,702.948
88,606.561
102,085.923
97,545.934
83,997.235
Net Interest Income
156,477.643
154,945.598
261,270.256
212,078.919
74,323.083
EBIT
3,000,997.701
2,894,752.828
2,484,752.469
2,428,096.544
2,329,686.064
EBITDA
3,000,997.701
3,469,888.936
3,325,076.101
3,080,420.588
2,774,957.373
Reconciled Cost of Revenue
4,049,948.231
4,081,106.957
4,465,473.361
4,461,283.076
4,253,087.484
Reconciled Depreciation
--
575,136.107
840,323.632
652,324.044
445,271.308
Net Income from Continuing Operation Net Minority Interest
2,089,979.926
2,061,095.804
1,953,650.833
1,909,407.688
1,775,683.251
Total Unusual Items Excluding Goodwill
-163,319.633
-159,000.909
-349,547.674
-196,154.213
-80,163.966
Total Unusual Items
-163,319.633
-159,000.909
-349,547.674
-196,154.213
-80,163.966
Normalized EBITDA
3,164,317.335
3,628,889.845
3,674,623.775
3,276,574.801
2,855,121.338
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-29,542.590
-28,424.963
-71,161.250
-31,560.172
-10,480.148
12/31/2021 - 1/16/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

000963.SZ Huadong Medicine Co., Ltd
39.29
+0.13%
 
3933.HK The United Laboratories International Holdings Limited
12.940
-0.46%
 
1681.HK CONSUN PHARMA
9.570
+1.81%
 
2633.HK Jacobson Pharma Corporation Limited
1.210
0.00%
 
6896.HK Golden Throat Holdings Group Company Limited
5.110
+5.36%
 
3692.HK Hansoh Pharmaceutical Group Company Limited
22.600
-0.44%
 
0013.HK HUTCHMED
20.800
-1.89%